Michael R. Schlabach
Q Therapeutics (United States)(US)
Publications by Year
Research Areas
CRISPR and Genetic Engineering, PARP inhibition in cancer therapy, Advanced biosensing and bioanalysis techniques, RNA modifications and cancer, DNA Repair Mechanisms
Most-Cited Works
- → A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene(2009)1,029 cited
- → Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening(2017)693 cited
- → Second-generation shRNA libraries covering the mouse and human genomes(2005)617 cited
- → Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5(2016)552 cited
- → Studying clonal dynamics in response to cancer therapy using high-complexity barcoding(2015)521 cited
- → A Genetic Screen for Candidate Tumor Suppressors Identifies REST(2005)499 cited
- → A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis(2011)435 cited
- → CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions(2016)395 cited
- → Cancer Proliferation Gene Discovery Through Functional Genomics(2008)386 cited
- → Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss(2018)356 cited